Tecentriq monoclonal antibody approved in China for the treatment of severe asthma and chronic sinusitis with nasal polyps.

On March 27th, AstraZeneca announced that Tezepelumab has been officially approved by the China National Medical Products Administration for two indications: as an additional maintenance treatment for adults and adolescents aged 12 and above with severe asthma; and for the treatment of chronic rhinosinusitis with nasal polyposis in adults who require systemic corticosteroids and/or surgery but cannot achieve disease control. Tezepelumab is the world's first and only approved anti-thymic stromal lymphopoietin monoclonal antibody, which acts on the top of the inflammatory cascade by blocking epithelial cell cytokine effects, for the treatment of severe asthma and chronic rhinosinusitis with nasal polyposis.